Increased prevalence of autoimmune phenomena in myelofibrosis: Relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns

Leukemia Research

Volumn 37, Issue 11, 2013, Pages 1509-1515

  Barcellini, Wilma ^a   Iurlo, Alessandra ^a   Radice, Tommaso ^a   Imperiali, Francesca Guia ^a   Zaninoni, Anna ^a   Fattizzo, Bruno ^a   Guidotti, Francesca ^a   Bianchi, Paola ^a   Fermo, Elisa ^a   Consonni, Dario ^a   Cortelezzi, Agostino ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Autoimmunity; Cytokines; Myelofibrosis

Indexed keywords

AUTOANTIBODY; BILIRUBIN; C REACTIVE PROTEIN; CYTOKINE; ERYTHROCYTE ANTIBODY; HAPTOGLOBIN; INTERLEUKIN 8; JANUS KINASE 2; LACTATE DEHYDROGENASE; TRANSFORMING GROWTH FACTOR BETA;

ACUTE HEART INFARCTION; ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; AUTOIMMUNE PHENOMENA; AUTOIMMUNITY; CD34 SELECTION; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CONTROLLED STUDY; COOMBS TEST; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOREGULATION; INFECTIOUS COMPLICATION; MAJOR CLINICAL STUDY; MALE; MITOGEN STIMULATED DIRECT ANTIGLOBULIN TEST; MUTATIONAL ANALYSIS; MYELOFIBROSIS; PREVALENCE; PRIORITY JOURNAL; RETICULOCYTE COUNT; RISK ASSESSMENT; RISK FACTOR; SKIN HEMANGIOMA; SPLENOMEGALY;

AUTOIMMUNITY; CYTOKINES; MYELOFIBROSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTI-IDIOTYPIC; AUTOIMMUNITY; COOMBS TEST; CYTOKINES; ERYTHROCYTES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-17; INTERLEUKIN-8; MALE; MIDDLE AGED; PREVALENCE; PRIMARY MYELOFIBROSIS; PROGNOSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84886787730     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.09.001     Document Type: Article

References (50)

1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000, 342:1255-1265.
2. Barosi G., Viarengo G., Pecci A., Rosti V., Piaggio G., Marchetti M., et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 2001, 98:3249-3255.
3. Tefferi A. How I treat myelofibrosis. Blood 2011, 117:3494-3504.
4. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010, 24(6):1128-1138.
5. Cervantes F., Dupriez B., Pereira A., Passamonti F., Reilly J.T., Morra E., et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113:2895-2901.
6. Passamonti F., Cervantes F., Vannucchi A.M., Morra E., Rumi E., Cazzola M., et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood 2010, 116:2857-2858.
7. Gangat N., Caramazza D., Vaidya R., George G., Begna K., Schwager S., et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011, 29:392-397.
8. Hasselbalch H. Idiopathic myelofibrosis: a clinical study of 80 patients. Am J Hematol 1990, 34(4):291-300.
9. Barosi G., Magrini U., Gale R.P. Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis?. Leuk Res 2010, 34(9):1119-1120.
10. Kristinsson S.Y., Landgren O., Samuelsson J., Björkholm M., Goldin L.R. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 2010, 95(7):1216-1220.
11. Bass R.D., Pullarkat V., Feinstein D.I., Kaul A., Winberg C.D., Brynes R.K. Pathology of autoimmune myelofibrosis. A report of three cases and a review of literature. Am J Pathol 2001, 116:211-216.
12. Tefferi A., Vaidya R., Caramazza D., Finke C., Lasho T., Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011, 29:1356-1363.
13. Hasselbalch H.C. The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev 2013, 24(2):133-145.
14. Skov V., Larsen T.S., Thomassen M., Riley C.H., Jensen M.K., Bjerrum O.W., et al. Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis. Eur J Haematol 2011, 87(1):54-60.
15. Skov V., Thomassen M., Riley C.H., Jensen M.K., Bjerrum O.W., Kruse T.A., et al. Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Exp Hematol 2012, 40(9):771-780.
16. Skov V., Larsen T.S., Thomassen M., Riley C.H., Jensen M.K., Bjerrum O.W., et al. Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance. Leuk Res 2012, 36(11):1387-1392.
17. Skov V., Riley C.H., Thomassen M., Larsen T.S., Jensen M.K., Bjerrum O.W., et al. Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis. Leuk Lymphoma 2013, 54(10):2269-2273.
18. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997, 18(6):263-266.
19. O'Shea J.J., Ma A., Lipsky P. Cytokines and autoimmunity. Nat Rev Immunol 2002, 2(1):37-45.
20. Romagnani S. Human Th17 cells. Arthritis Res Ther 2008, 10(2):206-214.
21. Moudgil K.D., Choubey D. Cytokines in autoimmunity: role in induction, regulation, and treatment. J Interferon Cytokine Res 2011, 31(10):695-703.
22. Barcellini W., Clerici G., Montesano R., Taioli E., Morelati F., Rebulla P., et al. In vitro quantification of anti-red blood cell antibody production in idiopathic autoimmune haemolytic anaemia: effect of mitogen and cytokine stimulation. Br J Haematol 2000, 111(2):452-460.
23. Barcellini W., Montesano R., Clerici G., Zaninoni A., Imperiali F.G., Calori R., et al. In vitro production of anti-RBC antibodies and cytokines in chronic lymphocytic leukemia. Am J Hematol 2002, 71:177-183.
24. Tefferi A., Thiele J., Vardiman J.W. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009, 115(September (17)):3842-3847. 10.1002/cncr.24440.
25. Gianelli U., Vener C., Bossi A., Cortinovis I., Iurlo A., Fracchiolla N.S., et al. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Mod Pathol 2012, 25(9):1193-1202.
26. Thiele J., Kvasnicka H.M., Facchetti F., Franco V., van der Walt J., Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005, 90(8):1128-1132.
27. Conrad K., Schossler W., Hiepe F. Autoantibodies in systemic autoimmune diseases: a diagnostic reference 2002, Babst Science Publishers, Lengerich.
28. Marsh W.L. Scoring of hemagglutination reactions. Transfusion (Paris) 1972, 12:352-353.
29. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
30. StataCorp Stata statistical software: release 12 2011, StataCorp LP, College Station.
31. Vener C., Fracchiolla N.S., Gianelli U., Calori R., Radaelli F., Iurlo A., et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood 2008, 111(4):1862-1865.
32. Elena C., Passamonti F., Rumi E., Malcovati L., Arcaini L., Boveri E., et al. Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica 2011, 96(1):167-170.
33. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352(17):1779-1790.
34. Campbell P.J., Baxter E.J., Beer P.A., Scott L.M., Bench A.J., Huntly B.J., et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 2006, 108(10):3548-3555.
35. Tefferi A., Lasho T.L., Huang J., Finke C., Mesa R.A., Li C.Y., et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008, 22:756-761.
36. Guglielmelli P., Barosi G., Specchia G., Rambaldi A., Lo Coco F., Antonioli E., et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009, 114:1477-1483.
37. Passamonti F., Rumi E., Elena C., Arcaini L., Merli M., Pascutto C., et al. Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. Br J Haematol 2010, 150(6):719-721.
38. Rumi E., Passamonti F., Bernasconi P., Arcaini L., Pietra D., Elena C., et al. Validation of cytogenetic-based risk stratification in primary myelofibrosis. Blood 2010, 115:2719-2720.
39. Barcellini W., Revelli N., Imperiali F.G., Villa M.A., Manera M.C., Paccapelo C., et al. Comparison of traditional methods and mitogen-stimulated direct antiglobulin test for detection of anti-red blood cell autoimmunity. Int J Hematol 2010, 91:762-769.
40. Dearden C., Wade R., Else M., Richards S., Milligan D., Hamblin T., et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 2008, 111(4):1820-1826.
41. Hayashi N., Koshiba M., Nishimura K., Sugiyama D., Nakamura T., Morinobu S., et al. Prevalence of disease-specific antinuclear antibodies in general population: estimates from annual physical examinations of residents of a small town over a 5-year period. Mod Rheumatol 2008, 18:153-160.
42. Hasselbalch H., Nielsen H., Berild D., Kappelgaard E. Circulating immune complexes in myelofibrosis. Scand J Haematol 1985, 34(2):177-180.
43. Teunissen M.B., Koomen C.W., de Waal Malefyt R., Wierenga E.A., Bos J.D. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998, 111:645-649.
44. Seddon B., Mason D. Regulatory T cells in the control of autoimmunity: the essential role of transforming growth factor beta and interleukin 4 in the prevention of autoimmune thyroiditis in rats by peripheral CD4(+)CD45RC- cells and CD4(+)CD8(-) thymocytes. J Exp Med 1999, 189:279-288.
45. Biernacka A., Dobaczewski M., Frangogiannis N.G. TGF-β signaling in fibrosis. Growth Factors 2011, 29:196-202.
46. Campanelli R., Rosti V., Villani L., Castagno M., Moretti E., Bonetti E., et al. Evaluation of the bioactive and total transforming growth factor β1 levels in primary myelofibrosis. Cytokine 2011, 53:100-106.
47. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14:6735-6741.
48. Barcellini W., Zaja F., Zaninoni A., Imperiali F.G., Battista M.L., Di Bona E., et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood 2012, 119:3691-3697.
49. Pisitkun P., Ha H.L., Wang H., Claudio E., Tivy C.C., Zhou H., et al. Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity 2012, 37:1104-1115.
50. Emadi S., Clay D., Desterke C., Guerton B., Maquarre E., Charpentier A., et al. IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation: differentiation, and ploidy in myeloid metaplasia with myelofibrosis. Blood 2005, 105(2):464-473.